DC Chemicals Limited
China
Product Name: Jnj-26076713
Price: ￥Inquiry/100mg ￥Inquiry/250mg ￥Inquiry/1g
Purity: 98.0%
Stocking Period: 10 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

669076-03-3

669076-03-3 structure

Name: JNJ-26076713
Chemical Name: (3S)-4-[1-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propanoyl]piperidin-4-yl]-3-[(3S)-1,2,3,4-tetrahydroquinolin-3-yl]butanoic acid
CAS Number: 669076-03-3
Molecular Formula: C₂₉H₃₈N₄O₃
Molecular Weight: 490.63700
Catalog: Signaling Pathways Cytoskeleton Integrin
Create Date: 2017-05-19 13:45:02
Modify Date: 2024-01-08 06:50:22
JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1].

Name	(3S)-4-[1-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propanoyl]piperidin-4-yl]-3-[(3S)-1,2,3,4-tetrahydroquinolin-3-yl]butanoic acid
Synonyms	unii-9dlk169hj7

Description	JNJ-26076713 is a potent and orally active alpha V integrin antagonist with IC50 values of 2.3 nM and 6.3 nM for alpha(V)beta(3) and alpha(V)beta(5), respectively. JNJ-26076713 inhibits retinal neovascularization[1].
Related Catalog	Research Areas >> Metabolic Disease Signaling Pathways >> Cytoskeleton >> Integrin
Target	αvβ3:2.3 nM (IC50) αvβ5:6.3 nM (IC50)
In Vitro	JNJ-26076713 (5-5000 nM) 以剂量依赖的方式抑制 FGF2 诱导的 HUVEC 迁移[1]。 JNJ-26076713 (0.1, 1, 和 10 μg) 以剂量依赖的方式抑制鸡胚绒毛尿囊膜 (CAM) 模型的血管生成[1].
In Vivo	JNJ-26076713 (30-120 mg/kg; i.g.; 每天两次, 连续5天; 氧诱导视网膜病变 (OIR) 模型C57BL/6J 小鼠) 以剂量依赖的方式抑制视网膜新生血管[1]。 JNJ-26076713 (60 mg/kg; i.g.; 每天两次, 连续5天; 糖尿病 Long-Evans 大鼠) 抑制与糖尿病相关的视网膜血管通透性和白细胞瘀血的增加[1]。 Animal Model: C57BL/6J mice with oxygen-induced retinopathy (OIR) model[1] Dosage: 30, 60, and 120 mg/kg Administration: Oral gavage, twice daily for 5 days Result: Inhibited retinal neovascularization with 33, 43, and 67% inhibition of neovascularization at 30, 60, and 120 mg/kg, respectively. Animal Model: Diabetic Long-Evans rats[1] Dosage: 60 mg/kg Administration: Oral gavage, twice daily for 5 days Result: Reduced leukocyte adhesion with 48% and inhibited retinal vascular permeability in streptozotocin diabetic rats.
References	[1]. Santulli RJ, et, al. Studies with an orally bioavailable alpha V integrin antagonist in animal models of ocular vasculopathy: retinal neovascularization in mice and retinal vascular permeability in diabetic rats. J Pharmacol Exp Ther. 2008 Mar;324(3):894-901.

Molecular Formula	C₂₉H₃₈N₄O₃
Molecular Weight	490.63700
Exact Mass	490.29400
PSA	94.56000
LogP	4.59020

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

669076-03-3	1259026-14-6
708275-58-5	951135-07-2
1917306-14-9	443797-96-4
1428327-35-8	871313-59-6
2086772-26-9	943540-75-8
1144493-60-6	1144448-97-4
1144493-81-1	1144493-86-6
1144493-87-7	1144467-65-1
1212438-04-4	1212440-27-1
1144493-96-8	1040692-92-9